A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)
Phase of Trial: Phase II
Latest Information Update: 14 May 2018
At a glance
- Drugs AZD 9567 (Primary) ; Prednisolone
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
- 26 Jan 2018 Planned End Date changed from 2 Jan 2019 to 15 Feb 2019.
- 26 Jan 2018 Planned primary completion date changed from 2 Jan 2019 to 15 Feb 2019.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.